ADCT
NYSE · Biotechnology
Adc Therapeutics Sa
$3.94
-0.11 (-2.72%)
Open$3.97
Previous Close$4.05
Day High$4.00
Day Low$3.87
52W High$4.80
52W Low$1.05
Volume—
Avg Volume940.4K
Market Cap519.05M
P/E Ratio—
EPS$-1.51
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+396.7% upside
Current
$3.94
$3.94
Target
$19.57
$19.57
$11.03
$19.57 avg
$23.80
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 92.30M | 72.20M | 66.42M |
| Net Income | -205,668,432 | -144,780,280 | 9.87M |
| Profit Margin | -222.8% | -211.7% | 14.9% |
| EBITDA | -152,548,603 | -113,352,501 | 12.50M |
| Free Cash Flow | — | — | 3.90M |
| Rev Growth | +27.9% | +27.9% | +3.3% |
| Debt/Equity | 3.72 | 3.72 | 0.73 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |